ADC Therapeutics SA held its annual general meeting on June 30, 2022, approved the election of Jean-Pierre Bizzari and Ameet Mallik as New Members of the Board of Directors. Jean-Pierre Bizzari, M.D., has been a non-executive member of Board of Directors since June 2022. He is a member of the scientific advisory board of France's National Cancer Institute and a board member of the European Organisation of Research and Treatment of Cancer.

From 2008 to 2015, Dr. Bizzari served as Executive Vice President, Group Head of Clinical Development Oncology at Celgene Corporation. Prior to that, he held various senior clinical development positions at Sanofi S.A., Aventis and Rhône-Poulenc. In addition to board of directors, Dr. Bizzari also serves as a member of the board of directors of Halozyme Therapeutics Inc., Oxford BioTherapeutics Limited, NETRIS Pharma SAS and Nordic Nanovector ASA, and previously served on the board of directors of Transgene S.A., Onxeo SA and Compugen Limited.

Dr. Bizzari holds an M.D. from Nice Medical School. Ameet Mallik, M.B.A., M.S, was appointed as Chief Executive Officer in May 2022 and has been a member of Board of Directors since June 2022. From 2005 to April 2021, Mr. Mallik served in various positions at Novartis, including as Executive Vice President and Head, U.S. Oncology from November 2017 to April 2021 and as Senior Vice President, Head of Global Marketing, Value and Access from November 2015 to November 2017.

Prior to that, Mr. Mallik held various commercial roles at Sandoz and was a Principal at McKinsey and Company. Most recently, from May 2021 to January 2022, Mr. Mallik served as the Chief Executive Officer of Rafael Holdings Inc. In addition to board of directors, Mr. Mallik also serves on the board of directors of Atara Biotherapeutics Inc. and Rafael Holdings Inc. Mr. Mallik holds an M.B.A. from The Wharton School at the University of Pennsylvania, and an M.S. in Biotechnology and B.S. in Chemical Engineering, both from Northwestern University.